Suggestions
Artal Moreno-Fortuny
Global Program Regulatory Manager at Novartis
Artal Moreno-Fortuny is currently the Global Program Regulatory Manager - Oncology at Novartis, where he plays a significant role in overseeing regulatory strategies for oncology products. His expertise is particularly valuable in navigating the complex regulatory landscape associated with innovative cancer therapies.
Professional Background
-
Current Role: As Global Program Regulatory Manager, Moreno-Fortuny is responsible for ensuring that Novartis's oncology products meet regulatory requirements throughout their development stages, from preclinical trials to market approval. This involves collaboration with various teams to align product development with regulatory standards and to facilitate successful submissions to health authorities.1
-
Previous Experience: He has a strong background in the pharmaceutical industry, having worked in various roles that emphasize regulatory affairs and product development. His contributions have been recognized in academic circles, where he has been mentioned for his insights into regulatory challenges and strategies in the field of oncology.13
Education and Skills
Moreno-Fortuny holds advanced degrees and has developed a comprehensive skill set that includes:
- Regulatory Affairs: Expertise in navigating the regulatory frameworks governing drug approval processes.
- Oncology Knowledge: In-depth understanding of oncology drug development and the specific challenges faced in this therapeutic area.
- Collaboration: Proven ability to work effectively with cross-functional teams to drive projects forward.
Contributions
His work has implications not only for Novartis but also for the broader field of oncology, as he engages in discussions about regulatory practices that can affect how new treatments are brought to market. He has been involved in significant discussions surrounding innovative therapies and their regulatory pathways, helping to shape best practices within the industry.12
Artal Moreno-Fortuny's professional journey reflects a commitment to improving cancer treatment through effective regulatory management and collaboration within the pharmaceutical sector.